Clene

Clene Profit per Employee

The Profit per Employee of Clene (CLNN) as of Nov 16, 2026 is -348,973.33 USD. In the previous year, Profit per Employee was -525,333.33 USD — a change of -33.57% (higher).

Profit per Employee

-348,973.33USD

YoY

-33.57%

Last updated:

Profit per Employee of Clene is 2025 -348,973.33 USD. Profit per Employee of Clene was 2024 -525,333.33 USD. It decreases by -33.57% higher compared to the previous year.

The Clene Profit per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Profit per Employee
Date
Profit per Employee
Jan 1, 2018
-3,697.48 USD
Jan 1, 2019
-215,400.00 USD
Jan 1, 2020
-257,026.67 USD
Jan 1, 2021
-129,866.67 USD
Jan 1, 2022
-398,906.67 USD
Jan 1, 2023
-660,053.33 USD
Jan 1, 2024
-525,333.33 USD
Jan 1, 2025
-348,973.33 USD
The Clene Profit per Employee history
YEARProfit per EmployeeYoY
-348,973.33USD-33.57%
-525,333.33USD-20.41%
-660,053.33USD+65.47%
-398,906.67USD+207.17%
-129,866.67USD-49.47%
-257,026.67USD+19.33%
-215,400.00USD+5,725.59%
-3,697.48USD+11,517.55%
-31.83USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Profit per Employee of Clene is -348,973.33 USD in 2025.

Profit per Employee of Clene changed from -525,333.33 USD to -348,973.33 USD, representing a -33.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Profit per Employee Clene since 2006 – with annual values, charts, and detailed analysis.

Profit per employee measures how much net income each employee generates on average. It is a key indicator of workforce efficiency.

Profit per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Profit per Employee's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Clene

All Key Metrics — Clene